Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 6/2018

01-12-2018 | Basic Science Foundations in Colorectal Cancer (DA Dixon and KE Hamilton, Section Editors)

Colorectal Cancer and Metabolism

Authors: Rachel E. Brown, Sarah P. Short, Christopher S. Williams

Published in: Current Colorectal Cancer Reports | Issue 6/2018

Login to get access

Abstract

Purpose of Review

Metabolic reprogramming is essential for the rapid proliferation of cancer cells and is thus recognized as a hallmark of cancer. In this review, we will discuss the etiologies and effects of metabolic reprogramming in colorectal cancer.

Recent Findings

Changes in cellular metabolism may precede the acquisition of driver mutations ultimately leading to colonocyte transformation. Oncogenic mutations and loss of tumor suppressor genes further reprogram CRC cells to upregulate glycolysis, glutaminolysis, one-carbon metabolism, and fatty acid synthesis. These metabolic changes are not uniform throughout tumors, as subpopulations of tumor cells may rely on different pathways to adapt to nutrient availability in the local tumor microenvironment. Finally, metabolic cross-communication between stromal cells, immune cells, and the gut microbiota enable CRC growth, invasion, and metastasis.

Summary

Altered cellular metabolism occurs in CRC at multiple levels, including in the cells that make up the bulk of CRC tumors, cancer stem cells, the tumor microenvironment, and host-microbiome interactions. This knowledge may inform the development of improved screening and therapeutics for CRC.
Literature
1.
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–91.CrossRefPubMed
2.
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.PubMedCrossRef
3.
Cronin KA, Lake AJ, Scott S, Sherman RL, Noone A-M, Howlader N, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124:2785–800.PubMedCrossRef
4.
5.
Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell NIH Public Access; 2012;21:297–308.
6.
•• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. This commentary by Hanahan and Weinberg updated their original “Hallmarks of Cancer” to include metabolic reprogramming.
7.
8.
Leninger A, Nelson D, Cox M. Lehninger principles of biochemistry. 7th ed. New York: Worth Publishers; 2017.
9.
Rich PR. The molecular machinery of Keilin’s respiratory chain. Biochem Soc Trans. 2003;31:1095–105.PubMedCrossRef
10.
The metabolism of tumours: investigations from the Kaiser Wilhelm Institute for Biology, Berlin-Dahlem. J Am Med Assoc. 1931;96:1982.
11.
12.
Weinhouse S, Warburg O, Burk D, Shade AL. On respiratory impairment in cancer cells. Science. 1956;124:267–269.
13.
Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010;330:1340–4.
14.
Fisel P, Schaeffeler E, Schwab M. Clinical and functional relevance of the monocarboxylate transporter family in disease pathophysiology and drug therapy. Clin Transl Sci. 2018;11:352–64.PubMedPubMedCentralCrossRef
15.
Maffione AM, Lopci E, Bluemel C, Giammarile F, Herrmann K, Rubello D. Diagnostic accuracy and impact on management of 18F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging. 2015;42:152–63.PubMedCrossRef
16.
Chung JK, Lee YJ, Kim C, Choi SR, Kim M, Lee K, et al. Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. J Nucl Med. 1999;40:339–46.PubMed
17.
Jiménez B, Mirnezami R, Kinross J, Cloarec O, Keun HC, Holmes E, et al. 1 H HR-MAS NMR spectroscopy of tumor-induced local metabolic “field-effects” enables colorectal cancer staging and prognostication. J Proteome Res. 2013;12:959–68.PubMedCrossRef
18.
•• Satoh K, Yachida S, Sugimoto M, Oshima M, Nakagawa T, Akamoto S, et al. Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC. Proc Natl Acad Sci U S A. 2017;114:E7697–706. This study showed that metabolic reprogramming occurs in response to MYC hyperactivation and does not correlate with mutations in APC, CTNNB1, or other genes involved in colorectal carcinogenesis.
19.
Furlan D, Sahnane N, Carnevali I, Cerutti R, Uccella S, Bertolini V, et al. Up-regulation and stabilization of HIF-1alpha in colorectal carcinomas. Surg Oncol. 2007;16(Suppl 1):S25–7.PubMedCrossRef
20.
Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, et al. GLUT1 glucose transporter expression in colorectal carcinoma. Cancer. 1998;83:34–40.PubMedCrossRef
21.
Wang J, Ye C, Chen C, Xiong H, Xie B, Zhou J, et al. Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8:16875–86.
22.
Feng W, Cui G, Tang C-W, Zhang X-L, Dai C, Xu Y-Q, et al. Role of glucose metabolism related gene GLUT1 in the occurrence and prognosis of colorectal cancer. Oncotarget. 2017;8:56850–7.PubMedPubMedCentralCrossRef
23.
Martins SF, Amorim R, Viana-Pereira M, Pinheiro C, Costa RFA, Silva P, et al. Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis. BMC Cancer. 2016;16:535.
24.
Graziano F, Ruzzo A, Giacomini E, Ricciardi T, Aprile G, Loupakis F, et al. Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. Pharmacogenomics. 2017;17:258–64.CrossRef
25.
He X, Lin X, Cai M, Zheng X, Lian L, Fan D, et al. Overexpression of hexokinase 1 as a poor prognosticator in human colorectal cancer. Tumor Biol. 2016;37:3887–95.CrossRef
26.
Ho N, Coomber BL. Hexokinase II expression is correlated with colorectal cancer prognosis. Cancer Treat Commun. 2016;6:11–6.
27.
Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, et al. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 2008;452:139–46.
28.
Nakayama Y, Torigoe T, Inoue Y, Minagawa N, Izumi H, Kohno K, et al. Prognostic significance of monocarboxylate transporter 4 expression in patients with colorectal cancer. Exp Ther Med. 2012;3:25–30.PubMedCrossRef
29.
Kim HK, Lee I, Bang H, Kim HC, Lee WY, Yun SH, et al. MCT4 expression is a potential therapeutic target in colorectal cancer with peritoneal carcinomatosis. Mol Cancer Ther. 2018;17:838–48.PubMedCrossRef
30.
Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer. 2004;91:980–4.PubMedPubMedCentralCrossRef
31.
Uppara M, Adaba F, Askari A, Clark S, Hanna G, Athanasiou T, et al. A systematic review and meta-analysis of the diagnostic accuracy of pyruvate kinase M2 isoenzymatic assay in diagnosing colorectal cancer. World J Surg Oncol. 2015;13:48.PubMedPubMedCentralCrossRef
32.
Wang J, Wang H, Liu A, Fang C, Hao J, Wang Z. Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer. Oncotarget. 2015;6:19456–68.PubMedPubMedCentralCrossRef
33.
Koukourakis MI, Giatromanolaki A, Simopoulos C, Polychronidis A, Sivridis E. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis. 2005;22:25–30.PubMedCrossRef
34.
35.
Li T, Le A. Glutamine metabolism in cancer. Adv Exp Med Biol. 2018;1063:13–32.
36.
Miyo M, Konno M, Nishida N, Sueda T, Noguchi K, Matsui H, et al. Metabolic adaptation to nutritional stress in human colorectal cancer. Sci Rep. 2016;6:38415.
37.
Alberghina L, Gaglio D. Redox control of glutamine utilization in cancer. Cell Death Dis. 2014;5:e1561–1.
38.
Liu G, Zhu J, Yu M, Cai C, Zhou Y, Yu M, et al. Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients. J Transl Med. 2015;13:144.PubMedPubMedCentralCrossRef
39.
Huang F, Zhang Q, Ma H, Lv Q, Zhang T. Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. Int J Clin Exp Pathol. 2014;7:1093–100.PubMedPubMedCentral
40.
Song Z, Wei B, Lu C, Li P, Chen L. Glutaminase sustains cell survival via the regulation of glycolysis and glutaminolysis in colorectal cancer. Oncol Lett. 2017;14:3117–23.PubMedPubMedCentralCrossRef
41.
Baenke F, Peck B, Miess H, Schulze A. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013;6:1353–63.PubMedPubMedCentralCrossRef
42.
• Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5:e189. This review discusses the many roles of lipid metabolism in cancer.
43.
Cohen S. Lipid droplets as organelles. Int Rev Cell Mol Biol. 2018;337:83–110.
44.
Notarnicola M, Messa C, Caruso MG. A significant role of lipogenic enzymes in colorectal cancer. Anticancer Res. 2012;32:2585–90.PubMed
45.
•• Notarnicola M, Tutino V, Calvani M, Lorusso D, Guerra V, Caruso MG. Serum levels of fatty acid synthase in colorectal cancer patients are associated with tumor stage. J Gastrointest Cancer. 2012;43:508–11. This paper describes the use of FASN inhibitors in patient-derived CRC xenograft tumor models.
46.
Zaytseva YY, Harris JW, Mitov MI, Kim JT, Butterfield DA, Lee EY, et al. Increased expression of fatty acid synthase provides a survival advantage to colorectal cancer cells via upregulation of cellular respiration. Oncotarget. 2015;6:18891–904.PubMedPubMedCentralCrossRef
47.
Zaytseva YY, Rychahou PG, Le A-T, Scott TL, Flight RM, Kim JT, et al. Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer. Oncotarget. 2018;9:24787–800.PubMedPubMedCentralCrossRef
48.
Karger S, Mika A, Kobiela J, Czumaj A, Chmielewski M, Stepnowski P, et al. Hyper-elongation in colorectal cancer tissue-cerotic acid is a potential novel serum metabolic marker of colorectal malignancies. Cell Physiol Biochem. 2017;41:722–30.CrossRef
49.
da Costa AC, Filho PRS, Júnior SA, de Oliveira FF, Begnami MD, de Lima VCC, et al. Prognostic value of factors associated with hypoxia and lipid metabolism in patients with colorectal cancer. Appl Cancer Res. 2017;37:44.CrossRef
50.
Fernández LP, Ramos-Ruiz R, Herranz J, Martín-Hernández R, Vargas T, Mendiola M, et al. The transcriptional and mutational landscapes of lipid metabolism-related genes in colon cancer. Oncotarget. 2018;9:5919–30.PubMedCrossRef
51.
Wen Y-A, Xiong X, Zaytseva YY, Napier DL, Vallee E, Li AT, et al. Downregulation of SREBP inhibits tumor growth and initiation by altering cellular metabolism in colon cancer. Cell Death Dis. 2018;9:265.PubMedPubMedCentralCrossRef
52.
Mutoh M, Komiya M, Teraoka N, Ueno T, Takahashi M, Kitahashi T, et al. Overexpression of low-density lipoprotein receptor and lipid accumulation in intestinal polyps in Min mice. Int J Cancer. 2009;125:2505–10.
53.
Accioly MT, Pacheco P, Maya-Monteiro CM, Carrossini N, Robbs BK, Oliveira SS, et al. Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. Cancer Res Am Assoc Cancer Res. 2008;68:1732–40.
54.
Hagland HR, Berg M, Jolma IW, Carlsen A, Søreide K. Molecular pathways and cellular metabolism in colorectal cancer. Dig Surg. 2013;30:12–25.PubMedCrossRef
55.
56.
Sánchez-Martínez R, Cruz-Gil S, de Cedrón MG, Álvarez-Fernández M, Vargas T, Molina S, et al. A link between lipid metabolism and epithelial-mesenchymal transition provides a target for colon cancer therapy. Oncotarget. 2015;6:38719–36.PubMedPubMedCentralCrossRef
57.
Cruz-Gil S, Sanchez-Martinez R, Gomez de Cedron M, Martin-Hernandez R, Vargas T, Molina S, et al. Targeting the lipid metabolic axis ACSL/SCD in colorectal cancer progression by therapeutic miRNAs: miR-19b-1 role. J Lipid Res. 2018;59:14–24.PubMedCrossRef
58.
Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O’Connor K, et al. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res. 2012;72:1504–17.PubMedPubMedCentralCrossRef
59.
Wang H, Xi Q, Wu G. Fatty acid synthase regulates invasion and metastasis of colorectal cancer via Wnt signaling pathway. Cancer Med. 2016;5:1599–606.PubMedPubMedCentralCrossRef
60.
• Newman AC, Maddocks ODK. One-carbon metabolism in cancer. Br J Cancer. 2017;116:1499–504. This review provides a broad overview of 1CM in cancer. PubMedPubMedCentralCrossRef
61.
• Ryall JG, Cliff T, Dalton S, Sartorelli V. Metabolic reprogramming of stem cell epigenetics. Cell Stem Cell. 2015;17:651–62. This review discusses the mechanisms by which metabolic intermediates contribute to epigenetic reprogramming. PubMedPubMedCentralCrossRef
62.
63.
Martinelli M, Scapoli L, Mattei G, Ugolini G, Montroni I, Zattoni D, et al. A candidate gene study of one-carbon metabolism pathway genes and colorectal cancer risk. Br J Nutr. 2013;109:984–9.PubMedCrossRef
64.
Liu AY, Scherer D, Poole E, Potter JD, Curtin K, Makar K, et al. Gene-diet-interactions in folate-mediated one-carbon metabolism modify colon cancer risk. Mol Nutr Food Res. 2013;57:721–34.PubMedCrossRef
65.
Jia X-Q, Zhang S, Zhu H-J, Wang W, Zhu J-H, Wang X-D, et al. Increased expression of PHGDH and prognostic significance in colorectal cancer. Transl Oncol. 2016;9:191–6.PubMedPubMedCentralCrossRef
66.
Ma L, Tao Y, Duran A, Llado V, Galvez A, Barger JF, et al. Control of nutrient stress-induced metabolic reprogramming by PKCζ in tumorigenesis. Cell. 2013;152:599–611.PubMedPubMedCentralCrossRef
67.
68.
Schell JC, Olson KA, Jiang L, Hawkins AJ, Van Vranken JG, Xie J, et al. A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol Cell. 2014;56:400–13.PubMedPubMedCentralCrossRef
69.
Lehuede C, Dupuy F, Rabinovitch R, Jones RG, Siegel PM. Metabolic plasticity as a determinant of tumor growth and metastasis. Cancer Res. 2016;76:5201–8.
70.
Puccini A, Berger MD, Naseem M, Tokunaga R, Battaglin F, Cao S, et al. Colorectal cancer: epigenetic alterations and their clinical implications. Biochim Biophys Acta. 1868;2017:439–48.
71.
Kim J-A, Yeom YI. Metabolic signaling to epigenetic alterations in cancer. Biomol Ther (Seoul). Korean Soc Appl Pharm. 2018;26:69–80.
72.
Zee BM, Levin RS, Xu B, LeRoy G, Wingreen NS, Garcia BA. In vivo residue-specific histone methylation dynamics. J Biol Chem. 2010;285:3341–50.PubMedCrossRef
73.
Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009;324:1076–80.PubMedPubMedCentralCrossRef
74.
75.
Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623–7.PubMedCrossRef
76.
77.
Luo Y, Yu M, Grady WM. Field cancerization in the colon: a role for aberrant DNA methylation? Gastroenterol Rep. 2014;2:16–20.CrossRef
78.
Patel A, Tripathi G, Gopalakrishnan K, Williams N, Arasaradnam RP. Field cancerisation in colorectal cancer: a new frontier or pastures past? World J Gastroenterol. 2015;21:3763–72.
79.
Backshall A, Alferez D, Teichert F, Wilson ID, Wilkinson RW, Goodlad RA, et al. Detection of metabolic alterations in non-tumor gastrointestinal tissue of the Apc Min/+ mouse by 1 H MAS NMR spectroscopy. J Proteome Res. 2009;8:1423–30.PubMedCrossRef
80.
Leclerc D, Lévesque N, Cao Y, Deng L, Wu Q, Powell J, et al. Genes with aberrant expression in murine preneoplastic intestine show epigenetic and expression changes in normal mucosa of colon cancer patients. Cancer Prev Res (Phila). 2013;6:1171–81.CrossRef
81.
Rao CV, Sanghera S, Zhang Y, Biddick L, Reddy A, Lightfoot S, et al. Systemic chromosome instability resulted in colonic transcriptomic changes in metabolic, proliferation, and stem cell regulators in Sgo1-/+ mice. Cancer Res NIH. 2016;76:630–42.CrossRef
82.
Cruz M Dela, Ledbetter S, Chowdhury S, Tiwari AK, Momi N, Wali RK, et al. Metabolic reprogramming of the premalignant colonic mucosa is an early event in carcinogenesis. Oncotarget. 2017;8:20543–57.
83.
Rao CV, Yamada HY. Genomic instability and colon carcinogenesis: from the perspective of genes. Front Oncol. 2013;3:130.
84.
Network TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.
85.
Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149:1192–205.
86.
•• Pate KT, Stringari C, Sprowl-Tanio S, Wang K, TeSlaa T, Hoverter NP, et al. Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer. Embo J. 2014;33:1454–73. This report was the first to establish a direct metabolic transcriptional target of WNT signaling.
87.
Roche TE, Baker JC, Yan X, Hiromasa Y, Gong X, Peng T, et al. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog Nucleic Acid Res Mol Biol. 2001;70:33–75.PubMedCrossRef
88.
Dang C V. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med. 2013;3.
89.
90.
91.
Yu M, Grady WM. Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. Therap Adv Gastroenterol. 2012;5:319–37.
92.
93.
Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39:171–83.PubMedPubMedCentralCrossRef
94.
Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495–501.PubMedPubMedCentralCrossRef
95.
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.
96.
Bentley J, Itchayanan D, Barnes K, McIntosh E, Tang X, Downes CP, et al. Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface. J Biol Chem. 2003;278:39337–48.PubMedCrossRef
97.
Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol. 2003;23:7315–28.PubMedPubMedCentralCrossRef
98.
Waldhart AN, Dykstra H, Peck AS, Boguslawski EA, Madaj ZB, Wen J, et al. Phosphorylation of TXNIP by AKT mediates acute influx of glucose in response to insulin. Cell Rep. 2017;19:2005–13.PubMedPubMedCentralCrossRef
99.
Roberts DJ, Tan-Sah VP, Smith JM, Miyamoto S. Akt phosphorylates HK-II at Thr-473 and increases mitochondrial HK-II association to protect cardiomyocytes. J Biol Chem. 2013;288:23798–806.PubMedPubMedCentralCrossRef
100.
Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem. 1997;272:17269–75.PubMedCrossRef
101.
102.
•• Hao Y, Samuels Y, Li Q, Krokowski D, Guan B-J, Wang C, et al. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nat Commun. 2016;7:11971. This report showed that PIK3CA mutations can reprogram CRC metabolism, increasing glutamine dependency.
103.
104.
Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.PubMedPubMedCentralCrossRef
105.
Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325:1555–9.
106.
Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K, et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science. 2015;350:1391–6.PubMedPubMedCentralCrossRef
107.
•• Hutton JE, Wang X, Zimmerman LJ, Slebos RJC, Trenary IA, Young JD, et al. Oncogenic KRAS and BRAF drive metabolic reprogramming in colorectal cancer. Mol Cell Proteomics. 2016;15:2924–38. This paper used a unique strategy to identify changes in levels of metabolic enzymes driven by oncogenic mutations in KRAS and BRAF. PubMedPubMedCentralCrossRef
108.
Chun SY, Johnson C, Washburn JG, Cruz-Correa MR, Dang DT, Dang LH. Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes. Mol Cancer. 2010;9:293.
109.
Sun Y, Liu Z, Zou X, Lan Y, Sun X, Wang X, et al. Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancer. J Bioenerg Biomembr. 2015;47:319–29.PubMedPubMedCentralCrossRef
110.
Fritsche-Guenther R, Zasada C, Mastrobuoni G, Royla N, Rainer R, Roßner F, et al. Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations. Sci Rep. 2018;8:9204.PubMedPubMedCentralCrossRef
111.
Lin S-C, Hardie DG. AMPK: sensing glucose as well as cellular energy status. Cell Metab. 2018;27:299–313.
112.
Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 2011;10:1394–406.PubMedCrossRef
113.
Blaser B, Waselle L, Dormond-Meuwly A, Dufour M, Roulin D, Demartines N, et al. Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells. BMC Cancer. 2012;12:86.PubMedPubMedCentralCrossRef
114.
Faes S, Duval AP, Planche A, Uldry E, Santoro T, Pythoud C, et al. Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors. Mol Cancer. 2016;15:78.PubMedPubMedCentralCrossRef
115.
Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015;349:1483–9.PubMedCrossRef
116.
Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer. 2009;9:691–700.
117.
Napoli M, Flores ER. The p53 family orchestrates the regulation of metabolism: physiological regulation and implications for cancer therapy. Br J Cancer. 2017;116:149–55.PubMedCrossRef
118.
Itahana Y, Itahana K. Emerging roles of p53 family members in glucose metabolism. Int J Mol Sci. 2018;19.
119.
Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004;64:2627–33.PubMedCrossRef
120.
Zawacka-Pankau J, Grinkevich VV, Hünten S, Nikulenkov F, Gluch A, Li H, et al. Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem. 2011;286:41600–15.PubMedPubMedCentralCrossRef
121.
Kawauchi K, Araki K, Tobiume K, Tanaka N. Loss of p53 enhances catalytic activity of IKKbeta through O-linked beta-N-acetyl glucosamine modification. Proc Natl Acad Sci U S A. 2009;106:3431–6.
122.
Contractor T, Harris CR. p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Res. 2012;72:560–7.
123.
Zhang C, Lin M, Wu R, Wang X, Yang B, Levine AJ, et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci U S A. 2011;108:16259–64.PubMedPubMedCentralCrossRef
124.
Kamp WM, Wang P-Y, Hwang PM. TP53 mutation, mitochondria and cancer. Curr Opin Genet Dev. 2016;38:16–22.
125.
126.
Lebedeva MA, Eaton JS, Shadel GS. Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis. Biochim Biophys Acta. 2009;1787:328–34.PubMedPubMedCentralCrossRef
127.
Bourdon A, Minai L, Serre V, Jais J-P, Sarzi E, Aubert S, et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet. 2007;39:776–80.
128.
Okamura S, Ng CC, Koyama K, Takei Y, Arakawa H, Monden M, et al. Identification of seven genes regulated by wild-type p53 in a colon cancer cell line carrying a well-controlled wild-type p53 expression system. Oncol Res. 1999;11:281–5.PubMed
129.
Matoba S, Kang J-G, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science. 2006;312:1650–3.PubMedCrossRef
130.
Li X-L, Zhou J, Chen Z-R, Chng W-J. P53 mutations in colorectal cancer—molecular pathogenesis and pharmacological reactivation. World J Gastroenterol. 2015;21:84–93.PubMedPubMedCentralCrossRef
131.
Bensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126:107–20.PubMedCrossRef
132.
Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A. 2010;107:7455–60.PubMedPubMedCentralCrossRef
133.
Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A. 2010;107:7461–6.
134.
Colangelo T, Polcaro G, Muccillo L, D’Agostino G, Rosato V, Ziccardi P, et al. Friend or foe?: the tumour microenvironment dilemma in colorectal cancer. Biochim Biophys Acta Rev Cancer. 2017;1867:1–18.PubMedCrossRef
135.
• De Francesco EM, Sotgia F, Lisanti MP. Cancer stem cells (CSCs): metabolic strategies for their identification and eradication. Biochem J. 2018;475:1611–34. This review provides a summary of CSC metabolism in many different cancer types.
136.
Hatano Y, Fukuda S, Hisamatsu K, Hirata A, Hara A, Tomita H. Multifaceted interpretation of colon cancer stem cells. Int J Mol Sci. 2017;18.
137.
Menendez JA, Alarcón T. Metabostemness: a new cancer hallmark. Front Oncol. 2014;4:262.
138.
Barker N, van de Wetering M, Clevers H. The intestinal stem cell. Genes Dev. Cold Spring Harbor Laboratory Press. 2008;22:1856–64.
139.
140.
De Lau W, Barker N, Low TY, Koo B-K, Li VSW, Teunissen H, et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature. 2011;476.
141.
Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 2007;449:1003–7.PubMedCrossRef
142.
Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature. 2009;457:603–7.PubMedCrossRef
143.
Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–5.PubMedCrossRef
144.
Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 2009;457:608–11.PubMedCrossRef
145.
• Rodríguez-Colman MJ, Schewe M, Meerlo M, Stigter E, Gerrits J, Pras-Raves M, et al. Interplay between metabolic identities in the intestinal crypt supports stem cell function. Nature. 2017;543:424–7. This report identified metabolic synergy between CBCs and Paneth cells in the intestinal stem cell niche.
146.
Rera M, Bahadorani S, Cho J, Koehler CL, Ulgherait M, Hur JH, et al. Modulation of longevity and tissue homeostasis by the Drosophila PGC-1 homolog. Cell Metab. 2011;14:623–34.PubMedPubMedCentralCrossRef
147.
Berger E, Rath E, Yuan D, Waldschmitt N, Khaloian S, Allgäuer M, et al. Mitochondrial function controls intestinal epithelial stemness and proliferation. Nat Commun. 2016;7:13171.PubMedPubMedCentralCrossRef
148.
149.
Fan Y-Y, Davidson LA, Callaway ES, Wright GA, Safe S, Chapkin RS. A bioassay to measure energy metabolism in mouse colonic crypts, organoids, and sorted stem cells. Am J Physiol Liver. 2015;309:G1–9.CrossRef
150.
Schell JC, Wisidagama DR, Bensard C, Zhao H, Wei P, Tanner J, et al. Control of intestinal stem cell function and proliferation by mitochondrial pyruvate metabolism. Nat Cell Biol. 2017;19:1027–36.PubMedPubMedCentralCrossRef
151.
Wei P, Dove KK, Bensard C, Schell JC, Rutter J. The force is strong with this one: metabolism (over)powers stem cell fate. Trends Cell Biol. 2018;28:551–9.
152.
Chen K-Y, Liu X, Bu P, Lin C-S, Rakhilin N, Locasale JW, et al. A metabolic signature of colon cancer initiating cells. Conf Proc Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:4759–62.
153.
Tirinato L, Liberale C, Di Franco S, Candeloro P, Benfante A, La Rocca R, et al. Lipid droplets: a new player in colorectal cancer stem cells unveiled by spectroscopic imaging. Stem Cells. 2015;33:35–44.PubMedCrossRef
154.
155.
• Reina-Campos M, Moscat J, Diaz-Meco M. Metabolism shapes the tumor microenvironment. Curr Opin Cell Biol. 2017;48:47–53. This review describes the metabolic interactions between cells in the TME. PubMedPubMedCentralCrossRef
156.
Marsh T, Pietras K, McAllister SS. Fibroblasts as architects of cancer pathogenesis. Biochim Biophys Acta - Mol Basis Dis. 2013;1832:1070–8.CrossRef
157.
Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol. 2014;25:47–60.PubMedCrossRef
158.
Avagliano A, Granato G, Ruocco MR, Romano V, Belviso I, Carfora A, et al. Metabolic reprogramming of cancer associated fibroblasts: the slavery of stromal fibroblasts. Biomed Res Int. 2018;2018:6075403.PubMedPubMedCentralCrossRef
159.
Fu Y, Liu S, Yin S, Niu W, Xiong W, Tan M, et al. The reverse Warburg effect is likely to be an Achilles’ heel of cancer that can be exploited for cancer therapy. Oncotarget. 2017;8:57813–25.PubMedPubMedCentralCrossRef
160.
Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118:3930–42.PubMedPubMedCentral
161.
• Wen Y-A, Xing X, Harris JW, Zaytseva YY, Mitov MI, Napier DL, et al. Adipocytes activate mitochondrial fatty acid oxidation and autophagy to promote tumor growth in colon cancer. Cell Death Dis. 2017;8:e2593. This paper demonstrated a direct role of tumor-associated adipocytes in CRC metabolism.
162.
Hong S, Cai Q, Chen D, Zhu W, Huang W, Li Z. Abdominal obesity and the risk of colorectal adenoma. Eur J Cancer Prev. 2012;21:523–31.PubMedCrossRef
163.
Dai Z, Xu Y-C, Niu L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol. 2007;13:4199–206.
164.
Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev. 2010;11:19–30.PubMedCrossRef
165.
Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013;119:1528–36.PubMedCrossRef
166.
• Hobson-Gutierrez SA, Carmona-Fontaine C. The metabolic axis of macrophage and immune cell polarization. Dis Model Mech. 2018;11. This review describes how immune cell polarization is triggered by intracellular metabolic reprogramming.
167.
Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med. 2018;24:1192–203.
168.
Parekh PJ, Balart LA, Johnson DA. The influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease. Clin Transl Gastroenterol. 2015;6:e91.
169.
• Loo JM, Scherl A, Nguyen A, Man FY, Weinberg E, Zeng Z, et al. Extracellular metabolic energetics can promote cancer progression. Cell. 2015;160:393–406. This paper demonstrated a novel mechanism by which CRC cells adapt to nutrient availability in the metastatic niche. PubMedPubMedCentralCrossRef
170.
Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59–65.PubMedPubMedCentralCrossRef
171.
Riaz Rajoka MS, Shi J, Mehwish HM, Zhu J, Li Q, Shao D, et al. Interaction between diet composition and gut microbiota and its impact on gastrointestinal tract health. Food Sci Hum Wellness. 2017;6:121–30.CrossRef
172.
Dusko ES. Metagenomics of the intestinal microbiota: potential applications. Gastroentérologie Clin Biol. 2010;34:S23–8.CrossRef
173.
Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312:1355–9.PubMedPubMedCentralCrossRef
174.
175.
Keku TO, Dulal S, Deveaux A, Jovov B, Han X. The gastrointestinal microbiota and colorectal cancer. Am J Physiol Gastrointest Liver. 2015;308:G351–63.CrossRef
176.
Purcell RV, Visnovska M, Biggs PJ, Schmeier S, Frizelle FA. Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Sci Rep. 2017;7:11590.PubMedPubMedCentralCrossRef
177.
Hullar MAJ, Burnett-Hartman AN, Lampe JW. Gut microbes, diet, and cancer. Cancer Treat Res. 2014:377–99.
178.
Sheflin AM, Whitney AK, Weir TL. Cancer-promoting effects of microbial dysbiosis. Curr Oncol Rep. 2014;16:406.
179.
Bhutia YD, Ogura J, Sivaprakasam S, Ganapathy V. Gut microbiome and colon cancer: role of bacterial metabolites and their molecular targets in the host. Curr Colorectal Cancer Rep. 2017;13:111–8.
180.
Parodi PW. Fatty acid composition of Australian butter and milk fats. Aust J Dairy Technol. 1970;25:200–205.
181.
McNabney S, Henagan T. Short chain fatty acids in the colon and peripheral tissues: a focus on butyrate, colon cancer, obesity and insulin resistance. Nutrients. 2017;9:1348.PubMedCentralCrossRef
182.
Wong JMW, de Souza R, Kendall CWC, Emam A, Jenkins DJA. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40:235–43.PubMedCrossRef
183.
Vital M, Gao J, Rizzo M, Harrison T, Tiedje JM. Diet is a major factor governing the fecal butyrate-producing community structure across Mammalia, Aves and Reptilia. ISME J. 2015;9:832–43.PubMedCrossRef
184.
Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. MBio. 2014;5:e00889.
185.
Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett. 2009;294:1–8.PubMedCrossRef
186.
Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012;6:320–9.PubMedCrossRef
187.
Balamurugan R, Rajendiran E, George S, Samuel GV, Ramakrishna BS. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol. 2008;23:1298–303.PubMedCrossRef
188.
Boutron-Ruault M-C, Marteau P, Lavergne-Slove A, Myara A, Gerhardt M-F, Franchisseur C, et al. Effects of a 3-mo consumption of short-chain fructo-oligosaccharides on parameters of colorectal carcinogenesis in patients with or without small or large colorectal adenomas. Nutr Cancer. 2005;53:160–8.PubMedCrossRef
189.
Monleón D, Morales JM, Barrasa A, López JA, Vázquez C, Celda B. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009;22:342–8.PubMedCrossRef
190.
Lupton JR. Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr. 2004;134:479–82.PubMedCrossRef
191.
Roediger WE. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology. 1982;83:424–9.PubMedCrossRef
192.
•• Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell. 2012;48:612–26. This seminal paper showed that the “butyrate paradox” is due to the differences in metabolic programming between normal enterocytes and CRC cells. PubMedPubMedCentralCrossRef
193.
Velcich A, Palumbo L, Jarry A, Laboisse C, Racevskis J, Augenlicht L. Patterns of expression of lineage-specific markers during the in vitro-induced differentiation of HT29 colon carcinoma cells. Cell Growth Differ. 1995;6:749–57.PubMed
194.
Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A. 1998;95:6791–6.PubMedPubMedCentralCrossRef
195.
• Li Q, Cao L, Tian Y, Zhang P, Ding C, Lu W, et al. Butyrate suppresses the proliferation of colorectal cancer cells via targeting pyruvate kinase M2 and metabolic reprogramming. Mol Cell Proteomics. 2018;17:1531–45. This report identified an HDAC-independent mechanism by which butyrate inhibits the growth of CRC cells.
196.
197.
Kaiko GE, Ryu SH, Koues OI, Collins PL, Solnica-Krezel L, Pearce EJ, et al. The colonic crypt protects stem cells from microbiota-derived metabolites. Cell. 2016;165:1708–20.
Metadata
Title
Colorectal Cancer and Metabolism
Authors
Rachel E. Brown
Sarah P. Short
Christopher S. Williams
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 6/2018
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-018-0420-y

Other articles of this Issue 6/2018

Current Colorectal Cancer Reports 6/2018 Go to the issue

Nutrition and Nutritional Interventions in Colorectal Cancer (K Wu, Section Editor)

The Role of Energy Balance on Colorectal Cancer Survival

Basic Science Foundations in Colorectal Cancer (DA Dixon and KE Hamilton, Section Editors)

Microbiome and Colorectal Cancer

Systemic Therapies in Colorectal Cancer (RD Kim, Section Editor)

Overview of Microsatellite Instability and Immune Checkpoint Inhibitors in Colorectal Cancer

Systemic Therapies in Colorectal Cancer (RD Kim, Section Editor)

What Is the Best Systemic Therapy for Left-sided RAS Wild-type Metastatic Colorectal Cancer?

Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

What Is the Future of Circulating Tumor Cells in Colorectal Cancer?

Systemic Therapies in Colorectal Cancer (RD Kim, Section Editor)

Novel Targets in Advanced Colorectal Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits